Semaglutide: FDA publishes warning amid reports of patients overdosing

The US Food and Drug Administration (FDA) has published a warning to the public and healthcare providers after receiving reports that patients are overdosing on semaglutide, with some requiring hospital admission.1FDA said the overdose reports it has received were related to “dosing errors involving compounded semaglutide injectable products dispensed in multiple dose vials.” It warned that in some instances, patients had administered five to 20 times more than the intended dose of the glucagon-like peptide-1 receptor agonist.Semaglutide, approved for the treatment of type 2 diabetes (Ozempic, Rybelsus), overweight or obesity (Wegovy), and to reduce the risk of cardiovascular events (Wegovy), is self-administered mainly in the form of single or multiple dose pre-filled pens.In light of ongoing shortages, some patients have received compounded versions of the drug. Compounded drugs can only be used in patients whose medical needs cannot be met by an available FDA approved drug. These custom preparations may…
Read Original Article: Semaglutide: FDA publishes warning amid reports of patients overdosing »